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Abstract
Introduction Bacterial meningitis (BM) is a severe complication
in patients with aneurysmal subarachnoid haemorrhage (SAH).
Clinical signs of meningitis are often masked by SAH-related
symptoms, and routine cerebrospinal fluid (CSF) analysis fails to
indicate BM. Microdialysis (MD) is a technique for monitoring
cerebral metabolism in patients with SAH. A cohort study was
performed to investigate the value of MD for the diagnosis of
BM.
Methods Retrospectively, 167 patients with SAH in an ongoing
investigation on cerebral metabolism monitored by MD were
analysed for the presence of BM and related MD changes.
Diagnosis of BM was based on microbiological CSF culture or
clinical symptoms responding to antibiotic treatment, combined
with an increased CSF cell count and/or fever. Levels of MD
parameters before and after diagnosis of BM were analysed and
compared with the spontaneous course in controls.
Results BM developed in 20 patients, of which 12 underwent
MD monitoring at the time of diagnosis. A control group was
formed using 147 patients with SAH not developing meningitis.
On the day BM was diagnosed, cerebral glucose was lower
compared with the value three days before (p = 0.012), and the
extent of decrease was significantly higher than in controls (p =
0.044). A decrease in cerebral glucose by 1 mmol/L combined
with the presence of fever ≥ 38°C indicated BM with a sensitivity
of 69% and a specificity of 80%. CSF chemistry failed to
indicate BM, but the cell count increased during the days before
diagnosis (p < 0.05).
Conclusions A decrease in MD glucose combined with the
presence of fever detected BM with acceptable sensitivity and
specificity, while CSF chemistry failed to indicate BM. In
patients with SAH where CSF cell count is not available or
helpful, MD might serve as an adjunct criterion for early
diagnosis of BM.
Introduction
Bacterial meningitis (BM) is a severe and cost-intensive com-
plication in patients with aneurysmal subarachnoid haemor-
rhage (SAH) and requires immediate treatment. Although
appropriate therapy with potent antibiotics is available, BM
continues to be associated with a prolonged stay in the inten-
sive care unit (ICU) and high morbidity [1]. External drainage
of cerebrospinal fluid (CSF), frequently applied especially in
patients with high-grade SAH, may raise the risk of infections
of the central nervous system (CNS). The diagnosis is difficult
in patients with SAH because the clinical signs of meningits
are often masked by SAH-related symptoms. Furthermore, an
alteration in CSF composition known as aseptic meningitis is
frequent after SAH and cannot reliably be distinguished from
CSF changes caused by BM [2]. Routine microbiological and
chemical analysis of CSF for the prediction or diagnosis of BM
failed in patients with external drains [3]. Considering these
restrictions and the risks associated with a delayed diagnosis
of BM, additional tools to facilitate the early diagnosis of BM
after SAH would be desirable.
Cerebral microdialysis (MD), an advanced neuromonitoring
technique, gives online information on the metabolic state of
the injured brain. This technique is mainly used to detect
ischaemia-related changes for early diagnosis of symptomatic
vasospasm in patients with SAH [4-6]. Additionally, it allows
quantification of interleukins and thereby provides analysis of
immunological processes within the brain, which may allow
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earlier therapeutic measures in the beginning of immunoreac-
tive cascades and thereby improve outcome in these patients
[7]. For investigating intracranial infections, the MD technique
has only been used in animal models and two case studies in
humans [8,9]. During experimental pneumococcal meningitis,
a decrease in cortical glucose levels and an increase in local
lactate production in the brain were observed [10]. Hence, the
present study aimed to evaluate whether cerebral MD allows
– besides the monitoring of ischaemia-related changes – the
early detection of BM, and to assess its significance compared
with CSF analysis and clinical changes.
Materials and methods
Patient population
Both this study and the underlying prospective investigation
on cerebral metabolism were approved by the Local Research
Ethics Committee at Charité Campus Virchow Medical
Center, in accordance with the Declaration of Helsinki as
revised in Edinburgh in October 2000. Written informed con-
sent was obtained from the patient or their nearest family rela-
tive.
Patients characteristics and management
Retrospectively, 170 consecutive patients with SAH, who
were part of an ongoing study on cerebral metabolism moni-
tored by bedside MD, were selected for analysis of MD
changes related to meningitis. All the patients had confirmed
aneurysmal SAH and underwent surgical treatment. Distribu-
tion and pattern of the haemorrhage were graded as proposed
by Fisher and colleagues [11], and clinical presentation was
graded according to the World Federation of Neurological
Surgeons (WFNS) scale [12]. Neurological outcome after six
months was assessed using the Glasgow outcome scale [13].
Demographic and clinical data are summarised in Table 1. In
the computed tomography (CT) scans of the patients, the
exact position of the MD catheter was reviewed. Three of the
170 patients were excluded because the catheter was situ-
ated close to an intracerebral haemorrhage, because in this
Table 1
Demographic and clinical characteristics of 167 patients following aneurysmal subarachnoid haemorrhage
All patients
(n = 167)
Meningitis
(n = 20)
Controls
(n = 147)
p
Age 50.8 ± 12.6 53.5 ± 9.7 50.4 ± 13.0 p = 0.292
Gender: male/female 46/121 5/15 41/106 p = 0.802
Admission WFNS grade 2.7 ± 1.6 3.6 ± 1.3 2.6 ± 1.6 p = 0.009
0 3 (2%) 0 (0%) 3 (2%)
I 58 (35%) 2 (10%) 56 (38%)
II 21 (13%) 3 (15%) 18 (12%)
III 18 (11%) 2 (10%) 16 (11%)
IV 38 (23%) 8 (40%) 30 (20%)
V 29 (17%) 5 (25%) 24 (16%)
Clinical group p = 0.867
Asymptomatic 66 (40%) 8 (40%) 58 (40%)
AFND 58 (35%) 6 (30%) 52 (35%)
DIND 43 (26%) 6 (30%) 37 (25%)
Time SAH – surgery (hours) 45.0 ± 74.4 61.0 ± 133.3 42.8 ± 62.3 p = 0.519
Fisher-score 3.0 ± 1.0 3.5 ± 0.6 3.0 ± 1.0 p = 0.059
Duration of microdialysis (hrs) 165.4 ± 83.8 185.2 ± 96.8 162.8 ± 81.9 p = 0.252
Presence of CSF drainage 77 (46%) 18 (90%) 59 (40%) p = 0.001
ICU stay (days) 15.1 ± 9.3 20.6 ± 6.9 14.3 ± 9.4 p = 0.003
GOS at 6 months after SAH 3.8 ± 1.4 4.0 ± 1.2 3.8 ± 1.4 p = 0.889
Mortality rate at 6 months 20 (13%) 1 (6%) 19 (14%) p = 0.322
P values are given for comparison of patients developing meningitis and controls (calculated by Mann-Whitney-U-Test or, for dichotomous data, 
by chi-squared test, exact versions).
AFND = acute focal neurological deficit; CSF = cerebrospinal fluid; DIND = delayed ischaemic neurological deficit; GOS = Glasgow outcome 
scale; ICU = intensive care unit; SAH = subarachnoid haemorrhage; WFNS = World Federation of Neurological Surgeons.Available online http://ccforum.com/content/13/1/R2
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area lactate and glutamate levels are known to be elevated
[14]. The remaining 167 patients were included in this analy-
sis.
Bedside microdialysis
In all patients, cerebral metabolism had been measured by an
MD catheter (CMA 70, CMA, Solna, Sweden); membrane
length 10 mm; molecular weight limit of 20 or 100 kD) in the
brain parenchyma of the corresponding vascular territory of
the aneurysm, with the catheter tip being located about 1.5 cm
from dura level. The correct positioning of the catheter tip
within the vascular territory of the occluded aneurysm was ver-
ified postoperatively by CT. Catheters were perfused with ster-
ile Ringer's solution at a flow rate of 0.3 μl/minute. The
estimated recovery for the system is 0.65 to 0.72 (recovery in
the two different catheter types is comparable for molecules
up to 20 kD) [15,16]. On the outlet tube, perfusates were col-
lected in microvials and analysed hourly at the bedside for
parameters of energy metabolism (glucose; pyruvate; lactate;
lactate/pyruvate (L/P) ratio; lactate/glucose (L/G) ratio) as
well as glycerol and glutamate, in a mobile photometric,
enzyme-kinetic analyser (CMA 600, CMA, Solna, Sweden).
MD was performed for 7 to 10 days after SAH, and daily medi-
ans of the microdialysate concentrations were calculated for
each patient.
Diagnosis of bacterial meningitis and evaluation of 
related microdialysate changes
The ICU records of the patients measured by MD were exam-
ined for the presence of fever of 38°C or above, the results of
microbiological and chemical CSF analysis, and the daily
records of the clinical state. Routine chemical CSF analysis in
patients with external drains included daily evaluation of cell
count, protein, glucose and lactate concentrations, as well as
microbiological culture in case of fever, changes in CSF chem-
istry and unclear neurological deterioration. In patients without
CSF drainage and suspicion of meningitis, CSF samples were
obtained by lumbar puncture. Patients with diagnosed BM
were recorded. In this retrospective study, patients were
accepted as having BM when the diagnosis was based on
either the presence of bacteria in CSF culture or on clinical
symptoms that rapidly responded to antibiotics typical for BM
treatment, in combination with increased CSF cell count and/
or fever of 38°C or above.
For assessment of BM-related changes in the composition of
cerebral extracellular fluid, the daily medians of microdialysate
concentrations were evaluated for three days preceeding the
diagnosis of BM up to day two after diagnosis. The same anal-
ysis was performed for CSF cell count and concentrations of
glucose, lactate and protein, as well as blood glucose concen-
trations. MD changes during three days before diagnosis of
BM were compared with the spontaneous course in the con-
trol group. In this analysis, only meningitis patients with a com-
plete MD dataset for this three-day period were included.
Because the onset of meningitis differed substantially
between patients, randomly selected periods of three days
were chosen in controls instead of the mean interval between
haemorrhage and meningitis. These periods were selected by
computer individually for each patient. Several repetitions of
this procedure with different, randomly selected intervals
brought comparable results.
Data analysis
The MD and CSF data were collected during days 1 to 10
after SAH. Data in tables and text are expressed as mean ±
standard deviation, if not otherwise specified. Statistical anal-
ysis was based on each patient's daily median values for each
MD variable and on daily CSF samples. Average microdia-
lysate values given for a group of patients were established
calculating the mean value of the patients' individual daily
medians for the MD parameters. Between group comparisons
were performed by nonparametric Mann-Whitney U tests and
chi-squared tests for dichotomous data (exact versions). Anal-
ysis of sequential data over time was performed using Wil-
coxon signed-rank test. Sensitivity and specificity of changes
in MD parameters for diagnosis of BM were evaluated in all the
patients undergoing MD monitoring at the time of meningitis.
They were calculated for MD changes alone and in combina-
tion with fever of 38°C of above. Results were displayed by
receiver operating curves, and the cutoff value for MD
changes that showed the highest sum of sensitivity and spe-
cificity was calculated. Statistics were calculated using SPSS
14.0 (SPSS Inc., Chicago, IL, USA) and R, Version 2.6.0 (The
R Foundation for Statistical Computing, Vienna, Austria). Dif-
ferences were considered statistically significant at p < 0.05.
Results
Patients
Results from 1.025 daily MD medians and 77 CSF samples in
167 patients were analysed. Twenty patients (12%) had been
diagnosed with BM by the physician in charge. All of them fit
this study's criteria for meningitis and were included. At the
time of meningitis 12 of the patients were undergoing MD
monitoring and in eight patients MD values were available for
the complete three-day-period before diagnosis of BM.
In 10 patients (50%), diagnosis of BM was based on microbio-
logical CSF findings (six patients had MD monitoring at the
time of diagnosis). Microbiological characteristics of these
patients are shown in Table 2. In a further 10 patients, diagno-
sis was based on CSF changes and clinical symptoms
responding to antibiotic treatment typically used for BM (four
patients had MD monitoring at the time of diagnosis). One
patient had already received antibiotic treatment before diag-
nosis of BM (in this case, BM was confirmed by microbiology).
CSF values were available for 14 patients with BM. A control
group was formed using 147 patients with SAH who did not
develop any CNS infection during the observation period.Critical Care    Vol 13 No 1    Schlenk et al.
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Risk factors and outcome in patients with SAH 
developing bacterial meningitis
Patients developing BM were more severely affected by the
haemorrhage than controls (WFNS grade: p = 0.01). This is
most likely to be due to the fact that in patients with high-grade
SAH a CSF drainage, known as a risk factor for BM, was
present more frequently than in controls. Almost all patients
with BM had CSF drainage (90%), but only 40% of patients
not developing CNS infections had a CSF drainage (p <
0.001). On the day of diagnosis of BM, a CSF drainage had
been present for 7.63 ± 3.2 days (range 2 to 14 days), and the
actual drainage had been present for 6.69 ± 3.4 days (range
1 to 14 days).
In this small group of patients with BM, mortality rate or neuro-
logical outcome at six months after SAH did not differ signifi-
cantly from controls. ICU stay was prolonged by 38% in
patients with BM (20.4 ± 7.6 vs. 14.8 ± 9.7 days after exclud-
ing patients who died during ICU stay; p = 0.003; Figure 1).
CSF and MD changes related to bacterial meningitis
During the time span from three days before to two days after
diagnosis of BM, no significant changes in CSF glucose, lac-
tate or protein concentrations were observed. CSF cell count,
however, was significantly higher on the day of diagnosis than
three (p = 0.028) and two (p = 0.01) days before. It should be
mentioned that in some patients the diagnosis of BM was
based on this elevation in CSF cell count, so the role of this
parameter as an independent indicator of BM cannot be relia-
bly evaluated in this study.
In cerebral extracellular fluid analysed by MD, changes in glu-
cose and L/G ratio were observed. On the day BM was diag-
nosed, cerebral glucose was lower (p = 0.012) and the L/G
ratio higher (p = 0.036) compared with three days before (Fig-
ure 2). The extent of decrease in glucose was significantly
higher than in controls (p = 0.044), while the course of L/G
ratio did not differ significantly from the control group (MD
changes at three days before diagnosis of BM, compared with
randomly selected periods of three days in controls). The other
measured parameters showed no significant changes during
the three days before diagnosis of BM. During this period of
time, there was no significant change in blood glucose con-
centrations in this group of patients, which would naturally
have to be considered as a cause of changes in cerebral glu-
cose, independent of meningitis (Figure 3).
The cutoff value for a decrease in MD glucose that showed the
highest sum of sensitivity and specificity for indication of BM
was 1 mmol/L. The diagnostic power of cerebral glucose
changes and fever is summarised in Table 3. A decrease of 1
mmol/L over any time span identified BM with a sensitivity of
92% and a specificity of 50% (Figure 4), while the presence
of fever (≥ 38°C) together with a glucose decrease of 1 mmol/
L reached a sensitivity of 69% and a specificity of 80% (Figure
5).
Discussion
This study aimed to assess the value of cerebral MD for diag-
nosis of BM in patients with SAH. There are three major find-
ings. First, ICU stay was prolonged by an average of six days
in patients with SAH and BM. Second, CSF chemistry failed
to indicate BM in the observed patients, although CSF cell
count showed a significant increase. Third, a decrease in cer-
ebral glucose by 1 mmol/L measured by MD combined with
the presence of fever detected BM with a sensitivity of 69%
and specificity of 80%.
Table 2
Microbiological characteristics of 10 patients with bacterial 
meningitis after aneurysmal subarachnoid haemorrhage.
Causative agent Number of patients
Staphylococcus aureus 4
Coagulase-negative Staphylococci 6
S. epidermidis 2
S. warneri 1
S. capitis 1
Acinetobacter baumannii 1
Escherichia coli 1
Bacteria were identified by microbiological culture of cerebrospinal 
fluid. In some patients, more than one organism was found.
Figure 1
Length of stay in the intensive care unit (ICU) in patients with aneurys- mal subarachnoid haemorrhage (SAH) Length of stay in the intensive care unit (ICU) in patients with 
aneurysmal subarachnoid haemorrhage (SAH). Box plot presenting 
ICU stay in patients with SAH and meningitis, and in patients with SAH 
and no infections of the central nervous system. Patients who died dur-
ing the ICU stay were excluded. Boxes represent 25th, 50th and 75th 
percentiles; dots mark the outlier values. P values were calculated 
using Mann-Whitney U test (exact version).Available online http://ccforum.com/content/13/1/R2
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Significance of CNS infections in patients with SAH
Hydrocephalus is a frequent complication after SAH and is
usually treated by external CSF drainage, so this patient group
is at risk of CNS infections [17]. The MD catheter itself might
also be a port of entry for bacteria, but MD monitoring has not
been reported to be associated with an increased risk of CNS
infections [4,18,19]. With an incidence of between 1 and 9
per 100 patients, CNS infections are among the most com-
monly documented infections in neurointensive care units
[17,20-22]. In a recent study in a large SAH population, men-
ingitis/ventriculitis occurred in 5% of patients and was the
fourth most common nosocomial infection after pneumonia
(20%), urinary tract infections (13%) and bloodstream infec-
tions (8%) [1]. In that study, older age, greater severity of SAH,
presence of intraventricular haemorrhage or ventricular drains,
and longer ICU stay were identified as risk factors for CNS
infection. An increased rate of death or severe disability could
not be shown, consistent with another investigation among
638 patients treated with CSF drainage [17]. Infection rates
appear not to be reduced by routine exchange of the drain, but
only by shortening the total draining time [23,24].
Diagnosis of bacterial meningitis in patients with SAH
Diagnosis of BM is usually based on clinical symptoms and
changes in CSF composition [25]. These are, however, of lim-
ited predictive value even in patients without additional neuro-
logical disease [26]. In patients with SAH, clinical symptoms
are even more unreliable, because most of the typical signs of
meningitis such as headache, nuchal rigidity and altered men-
tal status cannot safely be distinguished from SAH-related
symptoms. Fever is also an unreliable diagnostic marker. Due
to impaired cerebral temperature regulation after SAH, ele-
vated body temperatures can also occur spontaneously or be
absent in cases of severe infection. Additionally, respiratory
and urinary tract infections are more frequent in these patients
than BM, so suspect of meningitis is often raised late if there
are no typical clinical or CSF findings. However, CSF compo-
sition is frequently altered by biochemical reactions to the sub-
arachnoid blood and therefore unreliable. Typical CSF
changes can also be absent if patients are already receiving
antibiotic treatment for other infections such as pneumonia. In
our study, only cell count showed a significant BM-related
increase, but cannot reliably be evaluated because diagnosis
of BM was based on that parameter in some patients. In gen-
Figure 2
Cerebral extracellular glucose and lactate/glucose ratio in patients with  aneurysmal subarachnoid haemorrhage (SAH) and bacterial meningitis Cerebral extracellular glucose and lactate/glucose ratio in patients 
with aneurysmal subarachnoid haemorrhage (SAH) and bacterial 
meningitis. Individual courses of (a) cerebral extracellular glucose and 
(b) lactate/glucose (L/G) ratio in patients with SAH and bacterial men-
ingitis. Daily median microdialysate concentrations on three days 
before diagnosis of meningitis and on the day of diagnosis are pre-
sented for those patients with a complete dataset for that period. Each 
line represents one individual patient. P values were calculated using 
Wilcoxon signed-rank test.
Figure 3
Blood glucose in patients with aneurysmal subarachnoid haemorrhage  (SAH) and bacterial meningitis Blood glucose in patients with aneurysmal subarachnoid haemor-
rhage (SAH) and bacterial meningitis. Individual courses of blood 
glucose in patients with SAH and bacterial meningitis. Concentrations 
on three days before diagnosis of meningitis and on the day of diagno-
sis are presented for those patients with a complete dataset for that 
period. Each line represents one individual patient. P values were cal-
culated using Wilcoxon signed-rank test.Critical Care    Vol 13 No 1    Schlenk et al.
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eral, CSF leucocyte count after SAH is often altered by blood
cells and can even be impossible to evaluate in extremely
bloody CSF. The insufficiency of CSF analysis for diagnosis of
BM in these patients was strikingly demonstrated by Schade
and colleagues [3]. In a study investigating the value of routine
CSF analysis for diagnosis of BM in patients with external
drains, it was not possible to establish a cutoff value with a
sensitivity and specificity of at least 60% for any of the param-
eters of leucocyte count, protein, glucose and CSF/blood glu-
cose ratio. Gram stain of CSF samples reached a specificity of
99.9%, but sensitivity was as low as 39.8% [3]. Still, routine
CSF analysis remains recommended in patients with external
drains, but these data clearly illustrate the need for additional
tools to guide the diagnosis of bacterial meningitis in patients
with SAH.
Changes in MD parameters during bacterial meningitis
MD is used for monitoring cerebral metabolism in patients with
SAH. Among others, glucose and lactate levels are usually
assessed. The CSF concentrations of these markers are rou-
tinely used for diagnosis of BM, so their cerebral extracellular
concentrations can also be expected to indicate BM-related
changes. So far, MD data in meningitis are only available from
experimental studies carried out mainly for measurement of
drug penetration or pathophysiology of BM-related neuronal
injury, and from two case reports in humans.
An experimental study in rabbits with pneumococcal meningi-
tis revealed a cerebral increase in lactate and a decrease in
glucose, and the authors conclude that BM leads to anaerobic
glycolysis with increased lactate production within the brain
[10]. A trial evaluating the permeability of antibiotics across
the blood-brain barrier showed an increase in cerebral lactate
and glutamate, and a slight increase in glycerol towards the
end of the 24-hour observation period. Extracellular glucose
was not measured in that study [27]. In an investigation of MD
concentrations of several amino acids in a rabbit model of
pneumococcal meningitis, glutamate was greatly elevated and
was interpreted as an indicator that excitotoxic neuronal injury
may play a role in BM [28]. In rabbits undergoing Escherichia
coli meningitis, significant but late elevations in the excitatory
amino acids aspartate and glutamate as well as in the inhibi-
tory neurotransmitters γ-amino butyric acid and taurine were
Figure 4
Receiver operating curve (ROC) showing sensitivity and specificity of  cerebral glucose changes for diagnosis of bacterial meningitis Receiver operating curve (ROC) showing sensitivity and specificity 
of cerebral glucose changes for diagnosis of bacterial meningitis. 
Twelve patients with aneurysmal subarachnoid haemorrhage (SAH) 
and meningitis undergoing microdialysis measurement at the time of 
diagnosis and 141 without infections of the central nervous system 
were included. Data are given for maximum glucose decrease over vari-
able time spans within the observation period. Area under the curve 
(AUC) = 0.69, standard error = 0.07 (p = 0.026 compared with null 
hypothesis with AUC = 0.5). Blue line: Sensitivity and specificity of cer-
ebral glucose changes for diagnosis of meningitis; green line: sensitiv-
ity and specificity for null hypothesis.
Figure 5
Receiver operating curve (ROC) showing sensitivity and specificity of  cerebral glucose changes combined with presence of fever ≥ 38°C for  diagnosis of bacterial meningitis Receiver operating curve (ROC) showing sensitivity and specificity 
of cerebral glucose changes combined with presence of fever ≥ 
38°C for diagnosis of bacterial meningitis. Twelve patients with 
aneurysmal subarachnoid haemorrhage (SAH) and meningitis undergo-
ing microdialysis measurement at the time of diagnosis and 136 with-
out infections of the central nervous system were included. Data are 
given for maximum glucose decrease over variable time spans within 
the observation period. Area under the curve (AUC) = 0.74, standard 
error = 0.08 (p = 0.004 compared with null hypothesis with AUC = 
0.5). Blue line: Sensitivity and specificity of cerebral glucose changes 
with fever for diagnosis of meningitis; green line: sensitivity and specifi-
city for null hypothesis.Available online http://ccforum.com/content/13/1/R2
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observed, which the authors assume – in contrast to the pre-
ceeding study – to be caused by cerebral ischaemia because
of septic shock rather than the meningitis itself [29].
The available patient case reports focus on pathophysiological
disturbances in the course of BM, not on early metabolic
changes that could be used to guide diagnosis. In a patient
with BM after a severe head injury, cerebral glucose
decreased below the detection limit, combined with moder-
ately high lactate levels and a marked increase in glutamate
and pyruvate [8]. In another case of MD monitoring during
meningoencephalitis, L/P ratio and glycerol were reported to
remain stable, the other parameters were not mentioned [9].
Considering these results, a reduction in cerebral glucose and
an increase in lactate are most likely to be expected during
BM, eventually combined with an increase in glutamate. In the
present study, glucose decreased markedly in the days before
diagnosis of BM, but no significant changes in lactate, pyru-
vate or L/P ratio were noted. This might be due to the fact that
the lactate levels and the L/P ratio take different courses
according to the patient's clinical group (presence or absence
of acute/delayed neurological deficits), so BM-related
changes might have been obliterated by these alterations [4].
A significant change in glutamate was also not noted. A pos-
sible meningitis-related increase might have been masked by
the continuous glutamate decrease, which is part of the spon-
taneous course after SAH in the absence of ischaemia, or
have been oppressed by antibiotic treatment.
In how far the meningitis-related glucose depletion might limit
the cerebral energy supply and require specific treatment
remains speculative, although low cerebral glucose has been
shown to be associated with unfavourable outcome in trau-
matic brain injury and severe metabolic derangements in
patients with SAH [30,31].
In our study, a decrease in cerebral glucose of 1 mmol/L had
a high sensitivity (92%) but low specificity (50%) for the diag-
nosis of BM. Together with the presence of fever of 38°C or
above, acceptable sensitivity (69%) and specificity (80%)
were reached. This reduction in sensitivity when temperature
was included as a diagnostic factor can be explained by the
absence of fever in some patients with possible impaired tem-
perature regulation after SAH. As mentioned before, none of
the standard CSF parameters used for the diagnosis of BM
achieves a sensitivity or specificity of at least 60% in patients
with external ventricular drains [3]. Considering this, cerebral
MD might prove to be a useful tool not only to give pathophys-
iological insight in meningitis-related changes in brain metab-
olism, but also to facilitate diagnosis of BM in patients
undergoing MD monitoring for the detection of symptomatic
vasospasm, and thereby allowing earlier diagnosis and treat-
ment to improve outcome. However, its diagnostic value will
have to be confirmed prospectively in a larger patient popula-
tion.
Limitations of this study
There are several limitations of this study. Above all, the retro-
spective design did not allow exact definitions of the criteria
for diagnosis of BM, and some patients might have been
missed. No other infections simultaneously to BM were regis-
tered in the patient records. However, retrospectively, it can-
not be excluded that another infection was present in some
cases. Neither can the diagnostic value of the CSF cell count
for BM be evaluated in this study, because diagnosis of men-
ingitis had in some patients been based on this parameter
which would bias the statistical analysis. Furthermore, MD is a
regional method with the volume of brain tissue monitored by
the catheter covering only a few millimeters from the mem-
brane, and metabolic processes in the brain tissue affected by
SAH might not always be representative for the whole brain.
Finally, in spite of the large number of patients, only a few indi-
viduals sustained BM during the period of MD monitoring.
Therefore, this work should be considered a pilot study, and
Table 3
Diagnostic value of cerebral extracellular glucose and fever for bacterial meningitis in patients with aneurysmal subarachnoid 
haemorrhage
Glucose decrease ≥ 1 mmol/L Body temperature ≥ 38°C Glucose decrease ≥ 1 mmol/L AND body 
temperature ≥ 38°C
Sensitivity 92% 83% 69%
Specificity 50% 60% 80%
Positive predictive value 20.1% 22.1% 32.0%
Negative predictive value 97.9% 96.6% 95.0%
The results are displayed for a decrease in cerebral extracellular glucose of ≥ 1 mmol/L over variable time spans within the observation period, and 
for presence of fever ≥ 38°C. Positive and negative predictive values were calculated for a prevalence of meningitis of 12%, as found in the 
present study.Critical Care    Vol 13 No 1    Schlenk et al.
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the reliability of cerebral metabolic changes measured by MD
for diagnosis or prediction of BM in patients with SAH will
have to be confirmed prospectively in a substantially larger
study population. Nevertheless, this is the first study to our
knowledge evaluating cerebral metabolic changes during BM
in humans.
Conclusions
BM is a relevant complication in patients with SAH, and ICU
stay was prolonged by an average of 5.6 days in patients with
SAH and BM. The validity of clinical signs and routine CSF
analysis for the diagnosis of BM in patients with SAH is limited.
A decrease in MD glucose combined with the presence of
fever indicated BM with acceptable sensitivity and specificity,
while CSF chemistry including leucocyte count, protein and
glucose failed to indicate BM. In patients with SAH where
CSF cell count is not available or helpful, MD changes may
serve as an adjunct criterion for early diagnosis of BM. The
power of this study is limited because of the small patient
number and the retrospective design, so the results will have
to be confirmed in a larger, prospective study.
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